March 31 (Reuters) - Corcept Therapeutics CORT.O said on Monday its experimental ovarian cancer drug in combination with chemotherapy met the main goal of a late-stage trial.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shounak Dasgupta)
((Kamal.Choudhury@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.